Algeria Pharmaceuticals and Healthcare Report Q1 2009

Executive Summary ....................5
Algeria Pharmaceuticals And Healthcare Industry SWOT ............... 6
Pharmaceutical Business Environment Ratings ...7
Table: Middle East And North Africa Pharmaceutical Business Environment Ratings for Q109 ................ 7
Limits Of Potential Returns.................................. 8
Risks To Realisation Of Returns .......................... 8
Algeria – Market Summary ........10
Regulatory Regime....................11
Trade Agreements................. 11
Intellectual Property Environment..................... 12
Intellectual Property Shortcomings ................... 12
Pricing And Reimbursement Regime.................. 14
Industry Trends And Developments .....................15
Epidemiology........................ 15
Table Algeria – Top 10 Causes Of Death For All Ages (2002)....... 15
Healthcare Sector ................. 16
Domestic Pharmaceutical Sector....................... 17
Recent Domestic Pharmaceutical Sector Developments ................. 18
Pharmaceutical Wholesale ................................ 19
Pharmaceutical Retail .......... 20
Foreign Pharmaceutical Sector ......................... 20
Recent Foreign Pharmaceutical Sector Developments ................... 22
Biotechnology And Research ............................. 22
Medical Devices.................... 23
Industry Forecast Scenario .......24
Overall Market Forecast....... 24
Table: Algeria’s Drug Expenditure Indicators, 2003-2013 ............ 25
Key Growth Factors – Industry.......................... 26
Table: Health Expenditure Trends, 2003-2013 (US$bn)................. 27
Key Growth Factors – Macroeconomic.................28
It’s Oil Or Nothing................ 28
Enjoying The Gold Rush ....... 28
Steady Public Sector ............. 29
Risks To Outlook................... 29
Table: ALGERIA – ECONOMIC ACTIVITY...... 30
Prescription Market Forecast ............................ 31
Table: Algeria’s Prescription Market Indicators, 2003-2013 (DZDmn unless otherwise stated) .............. 32
Patented Drug Market Forecast ........................ 33
Table: Algeria’s Patented Drug Market, 2003-2013....................... 34
Generics Market Forecasts................................ 35
Table: Algeria’s Generics Market Indicators, 2003-2013 .............. 35
OTC Market Forecast........... 36
Table: Algeria’s OTC Market Indicators, 2003-2013 (DZDmn unless otherwise stated) .......................... 37
Export And Import Forecasts............................. 38
Table: Algeria’s Pharmaceutical Trade Indicators, 2003-2013 (US$mn) .................... 39
Other Healthcare Data Forecasts...................... 39
Table: Algeria – Other Healthcare Data And Forecasts, 2003-2013............................ 39
Key Risks To BMI’s Forecast Scenario.............. 40
Competitive Landscape............41
Table Leading Pharmaceutical Companies In Algeria ................... 42
Company Profiles......................43
Leading Multinationals.............. 43
Sanofi-Aventis....................... 43
GlaxoSmithKline (GSK)........ 45
Pfizer ....... 46
Novartis ................................ 48
Merck & Co .......................... 49
Leading Indigenous Manufacturer.......................... 50
Groupe Saidal....................... 50
Country Snapshot: Algeria Demographic Data....52
Section 1: Population............ 52
Table: Demographic Indicators, 2005-2030...... 52
Table: Rural/Urban Breakdown, 2005-2030 ..... 53
Section 2: Education And Healthcare................ 53
Table: Education Levels, 2002-2025 ................. 53
Table: Healthcare – Vital Statistics, 2005-2030 ............................. 53
Section 3: Labour Market And Spending Power ............................. 54
Table: Employment Indicators, 2001-2006........ 54
Table: Consumer Expenditure, 2000-2012 (US$) ........................... 55
BMI Forecast Modelling............56
How We Generate Our Pharmaceutical Industry Forecasts ................ 56
Pharmaceutical Business Environment Ratings Methodology ............. 57
Ratings Overview.................. 57
Table: Pharmaceutical Business Environment Indicators .............. 58
Weighting.............................. 58
Table: Weighting Of Components...................... 59
Sources ......... 59